SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant retail and institutional interest, fueled by a positive feature in the Wall Street Journal and community enthusiasm surrounding the company's expanding role in physical AI, robotics, and its QNX software platform. Investors are closely monitoring volume and price action as the community discusses potential breakouts, institutional accumulation, and the stock's long-term growth potential in cybersecurity and automotive technology.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging following an earnings report that emphasized improved profit margins and robust AI infrastructure demand, helping to alleviate concerns regarding recent legal and regulatory overhangs. Investors and community members are actively debating the company's valuation gap compared to sector peers and monitoring whether this momentum can sustain a potential short squeeze.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending after NOAA officially determined the company's deep-seabed mining application is in full compliance, providing a clear regulatory path toward commercial recovery permits by 2027. Investors are actively discussing this milestone as a major de-risking event, with many debating the stock's long-term potential as a critical component in the domestic battery metal supply chain.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant community buzz as investors anticipate potential global partnership announcements and updates regarding its AI-driven immunotherapy manufacturing technology. The discussion is heavily centered on a potential short squeeze, with retail traders pointing to high short interest and limited float as key drivers for a potential sharp upward move.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings Inc. (CELH) is experiencing extreme volatility as shares touch new 52-week lows, fueling intense community debate regarding institutional manipulation versus fundamental concerns like competition from private-label alternatives. Investors are closely monitoring the upcoming earnings release, with many split between those expecting a massive post-earnings rebound and those fearing further downside due to inventory and margin pressures.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubo is experiencing significant volatility as retail investors debate the company's long-term viability and the impact of its partnership with Disney, while the stock faces heavy short interest and skepticism regarding management's profitability targets. The community remains deeply polarized, with bulls pointing to potential strategic synergies and oversold conditions, while bears cite historical subscriber losses and a lack of insider buying as reasons to avoid the stock.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as market sentiment turns bullish, driven by expectations of a blockbuster year for Briumvi, strong commercial execution, and anticipation of upcoming trial readouts for subcutaneous formulations and Azer-cel. The community is actively discussing the potential for a strategic buyout and observing significant institutional accumulation, which many believe is positioning the stock for a breakout beyond current resistance levels.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is seeing high volatility and intense social media discussion as investors debate its valuation ahead of upcoming earnings, with bull-case optimism centering on potential government contracts and strategic acquisitions while bears express concerns over cash burn and dilution. Traders are heavily focused on the stock's recent price swings and potential for a short squeeze, leading to a highly polarized community dialogue regarding the company's long-term quantum computing prospects.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending following a manufacturing collaboration announcement for its ERNA-101 ovarian cancer therapy, driving significant volatility and volume. The community is sharply divided, with bulls pointing to the potential for a short squeeze on the low-float asset, while skeptics warn of historical dilution and the risks inherent in early-stage preclinical biotech.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the subject of intense retail and institutional debate as investors weigh the stock's significant options flow and recent semiconductor infrastructure news against concerns regarding technical resistance levels and valuation. The community is actively split, with bulls pointing to the company's long-term potential in AI, robotics, and energy to justify current positioning, while bears highlight persistent regulatory hurdles, recall news, and historical price volatility as reasons for caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?

Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.

Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals

Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before...

NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up

Novo Nordisk stock jumps as Q1 earnings and revenues beat estimates, fueled by strong Wegovy and Ozempic demand and a raised 2026 outlook.

Private Payrolls Increased More Than Expected

ADP +109K: Job Growth on Lower-Paying Work

Beyond obvious strength in Healthcare, we're starting to see "green shoots" in industries that a year ago were seeing negative growth.

Novo Raises Forecast as Wegovy Pill Fuels Sales

Novo Nordisk said this year's declines won't be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit...

Deja Vu All Over Again: Futures Surge, Oil Tumbles On Iran Deal Optimism, Tech Rally

Deja Vu All Over Again: Futures Surge, Oil Tumbles On Iran Deal Optimism, Tech Rally US equity futures are up big this morning and making fresh all time highs, led by tech companies, while oil prices...

Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook

Novo Nordisk ($NVO) stock jumps as the company raises 2026 guidance. Strong Q1 sales beat estimates, driven by massive GLP-1 drug demand.read more...

Novo Nordisk beats estimates and shares surge on demand for weight loss pill

First-quarter sales of the oral Wegovy pill hit $353 million, more than double analyst expectations, as the company lifted its full-year outlook...

'Project Freedom' Pause, Stocks Rally as AI Spend Drives Tech  The Opening Trade 5/6/2026

Technology stocks are driving rallies in global equities as a wave of blockbuster earnings and deals highlights the relentless pace of investment in artificial intelligence. Investors' optimism was...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Stocktwits

Stocktwits Polls

Novo Nordisk A/S

The oral Wegovy launch is shattering volume records with over 2 million prescriptions, signaling massive adoption.

Investors are pinning hopes on the CagriSema and Zenagamtide pipeline as potential long-term game changers.

Strong Q1 results and raised 2026 guidance are fueling investor optimism despite historical volatility.

Advantageous US manufacturing and retail pharmacy penetration are strengthening competitive positioning against peers.

Current Price	$46.09
Prev Close	$44.87
Open	$46.31
Dividend Yield	2.53%
50-Day Moving Average	$38.68
Beta	0.93
Avg. Volume	16.66M
PE Ratio	12.92

52-Week High	$81.44
52-Week Low	$35.12
Market Capitalization	$151.17B
EPS (Annual)	$3.49
Price to Book	6.54
Revenue Per Employee	$679,358.45

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News

NVONovo Nordisk A/S